Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease.
Inhibitors of the human immunodeficiency virus type 1 (HIV-1) protease represent a promising addition to the available agents used to inhibit virus replication in a therapeutic setting. HIV-1 is capable of generating phenotypic variants in the face of a variety of selective pressures. The potential to generate variants with reduced sensitivity to a protease inhibitor was examined by selecting for virus growth in cell culture in the presence of the protease inhibitor A-77003. Virus variants grew out in the presence of the inhibitor, and these variants encoded proteases with reduced sensitivity to the inhibitor. Variants were identified that encoded changes in each of the three subsites of the protease that interact with the inhibitor. HIV-1 displays significant potential for altering its interaction with this protease inhibitor, suggesting the need for multiple protease inhibitors with varying specificities.
Kaplan
A H
AH
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill 27599.
Michael
S F
SF
Wehbie
R S
RS
Knigge
M F
MF
Paul
D A
DA
Everitt
L
L
Kempf
D J
DJ
Norbeck
D W
DW
Erickson
J W
JW
Swanstrom
R
R
D000595:Amino Acid Sequence; D001483:Base Sequence; D017931:DNA Primers / Q000737:chemistry; D016333:HIV Protease / Q000235:genetics*; D017320:HIV Protease Inhibitors / Q000494:pharmacology*; D015497:HIV-1 / Q000201:enzymology* / Q000235:genetics; D007700:Kinetics; D008782:Methylurea Compounds; D008958:Models, Molecular; D008969:Molecular Sequence Data; D017354:Point Mutation; D011725:Pyridines; D016415:Sequence Alignment; D017386:Sequence Homology, Amino Acid; D014633:Valine / Q000031:analogs & derivatives
D017931:DNA Primers; D017320:HIV Protease Inhibitors; D008782:Methylurea Compounds; D011725:Pyridines; C079555:Abbott 77003; D016333:HIV Protease; D014633:Valine